Company Focus
AbbVie
Latest AbbVie News
Pharmaceutical
AbbVie today announced new Phase III data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. 12 June 2026
Related News
Insights
Company Spotlight
A cell therapy company developing programmed T cell therapies, with its lead program centered on a CD19-directed CAR-T for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Latest News & Features of interest to AbbVie
Generics
In a significant move to expand its oncology footprint in the United States, Indian major Dr Reddy’s Laboratories has announced the launch of Bosutinib 400mg tablets, the generic equivalent of Pfizer’s blockbuster drug Bosulif, used in the treatment of chronic myeloid leukemia (CML). 15 June 2026
Biotechnology
M&A featured heavily last week, with Incyte announcing plans to buy Vega Therapeutics, a subsidiary of Star Therapeutics, for up to $2 billion. Then came UK pharma major GSK’s revelation of an agreement to acquire US firm Nuvalent for up to $10.6 billion. Also of note, US biotech Cartesian Therapeutics entered into a licensing deal with China’s WestGene Biopharma on CAR-T therapies for autoimmune diseases. Sweden’s Camurus was served another complete response letter (CRL) by the US Food and Drug Administration (FDA) on its filing for Oclaiz (CAM2029). 14 June 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and prednisone as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer. 13 June 2026
Biotechnology
Rocket Pharmaceuticals announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million. The firm’s shares rose 5.6% to $2.81 following the announcement. 12 June 2026
Biotechnology
UK cell therapy company Autolus Therapeutics has won the 2026 Prix Galien UK Award for Best Biotechnology Product for Aucatzyl (obecabtagene autoleucel), its CAR-T therapy for adult acute lymphoblastic leukemia. 12 June 2026
Pharmaceutical
AbbVie today announced new Phase III data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. 12 June 2026
Biotechnology
US biopharma Adial Pharmaceuticals has acquired Azora Therapeutics and lined up a private placement worth up to $64 million, broadening its pipeline beyond its historical focus on addiction disorders. 12 June 2026
Biotechnology
The US Food and Drug Administration (FDA) has accepted Roche’s supplemental Biologics License Application (sBLA) filing for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs). 11 June 2026
Biotechnology
US biotech Beren Therapeutics has lined up a financing package worth up to $300 million to support preparations for the potential launch of adrabetadex, its investigational treatment for infantile-onset Niemann-Pick disease type C. 11 June 2026
Generics
Spanish pharma Reig Jofre has launched dalbavancin in Europe, adding a long-acting injectable antibiotic to its hospital anti-infectives portfolio as cheaper versions begin to reshape a specialized market. 11 June 2026
Latest In Brief for AbbVie
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze